JP Morgan Chase
MRNA icon

JP Morgan Chase’s Moderna MRNA Stock Holding History

JP Morgan Chase’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$43.8M Buy
907,300
+410,100
+82% +$19.1M ﹤0.01% 1481
2025
Q4 		$14.7M Buy
497,200
+361,100
+265% +$9.81M ﹤0.01% 2338
2025
Q3 		$3.52M Buy
136,100
+101,500
+293% +$2.83M ﹤0.01% 3654
2025
Q2 		$955K Sell
34,600
-65,200
-65% -$1.72M ﹤0.01% 4413
2025
Q1 		$2.83M Buy
99,800
+85,200
+584% +$3.02M ﹤0.01% 3605
2024
Q4 		$607K Sell
14,600
-7,600
-34% -$363K ﹤0.01% 4933
2024
Q3 		$1.48M Sell
22,200
-50,000
-69% -$4.59M ﹤0.01% 4230
2024
Q2 		$8.57M Buy
72,200
+69,700
+2,788% +$8.82M ﹤0.01% 2585
2024
Q1 		$266K Sell
2,500
-9,600
-79% -$968K ﹤0.01% 5187
2023
Q4 		$1.2M Hold
12,100
– – ﹤0.01% 4209
2023
Q3 		$1.25M Sell
12,100
-6,000
-33% -$669K ﹤0.01% 3910
2023
Q2 		$2.2M Buy
18,100
+300
+2% +$40K ﹤0.01% 3474
2023
Q1 		$2.73M Sell
17,800
-40,900
-70% -$6.75M ﹤0.01% 3313
2022
Q4 		$10.5M Buy
58,700
+28,400
+94% +$4.64M ﹤0.01% 2202
2022
Q3 		$3.58M Buy
30,300
+10,300
+52% +$1.56M ﹤0.01% 3017
2022
Q2 		$2.86M Sell
20,000
-126,500
-86% -$18.1M ﹤0.01% 3262
2022
Q1 		$25.2M Buy
146,500
+122,500
+510% +$20.6M ﹤0.01% 1584
2021
Q4 		$6.1M Buy
24,000
+23,000
+2,300% +$6.72M ﹤0.01% 2891
2021
Q3 		$385K Sell
1,000
-41,400
-98% -$15.3M ﹤0.01% 4874
2021
Q2 		$9.96M Sell
42,400
-141,600
-77% -$25.3M ﹤0.01% 2438
2021
Q1 		$24.1M Buy
184,000
+86,400
+89% +$12.5M ﹤0.01% 1597
2020
Q4 		$10.2M Sell
97,600
-287,200
-75% -$29.1M ﹤0.01% 2201
2020
Q3 		$27.1M Buy
384,800
+354,800
+1,183% +$24.7M ﹤0.01% 1303
2020
Q2 		$1.93M Hold
30,000
– – ﹤0.01% 3127
2020
Q1 		$899K Buy
+30,000
New +$690K ﹤0.01% 3462

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase's MRNA Position: Q1 2026 in Review

JP Morgan Chase increased its Moderna (MRNA) stake by 30% in Q1 2026, buying an estimated $14.2M and bringing the position to 1,317,601 shares worth $63.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1237.

JP Morgan Chase first reported a position in MRNA in Q4 2018 and has held it in 30 quarters since. The position peaked at $492M in Q3 2021. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • JP Morgan Chase held 1,317,601 shares of Moderna worth $63.5M as of Q1 2026.
  • JP Morgan Chase bought 303,717 Moderna shares in Q1 2026, an estimated $14.2M.
  • Moderna made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #1237 holding.
  • JP Morgan Chase first reported a position in Moderna in Q4 2018 and has held it in 30 quarters since.
  • JP Morgan Chase's Moderna position peaked at $492M in Q3 2021.
  • 722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.